Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors

Expert Opinion on Biological Therapy

Volumn 9, Issue 5, 2009, Pages 579-591

  Marcu Malina, Victoria ^a   Van Dorp, Suzanne ^a   Kuball, Jürgen ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Clinical trial; Genetic engineering; T body; TCR gene transfer

Indexed keywords

ALPHA FOLATE RECEPTOR; ANTIGEN; CARBONATE DEHYDRATASE IX; CARCINOEMBRYONIC ANTIGEN; CD171 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; FOLATE RECEPTOR; GANGLIOSIDE GD2; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100 154 162; INTERLEUKIN 13 RECEPTOR ALPHA2; MELAN A; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN P53; T LYMPHOCYTE ANTIBODY; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ADVANCED CANCER; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CELL EXPANSION; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE TRANSFER; GENETIC ENGINEERING; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; MANTLE CELL LYMPHOMA; MELANOMA; MEMORY T LYMPHOCYTE; METASTASIS; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARIAN EPITHELIAL CANCER; OVARY CANCER; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; T LYMPHOCYTE; TREATMENT OUTCOME;

ADOPTIVE TRANSFER; ANIMALS; CLINICAL TRIALS AS TOPIC; GENE TARGETING; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 67649101753     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902887018     Document Type: Review

References (105)

1. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15 (Pubitemid 32250041)
2. Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 2004;53:187-195 (Pubitemid 38328041)
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-915 (Pubitemid 39273730)
4. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-675 (Pubitemid 37328821)
5. Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007;109:2331-2338 (Pubitemid 46425872)
6. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002;2:512-519 (Pubitemid 37328742)
7. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008;329-342
8. Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999;163:507-513 (Pubitemid 29295880)
9. Willemsen RA, Weijtens ME, Ronteltap C, et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 2000;7:1369-1377 (Pubitemid 30662242)
10. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005;106:3062-3067 (Pubitemid 41565901)
11. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001;2:962-970 • This study demonstrates that T cells can be re-programmed with high-affinity TCRs by circumvention of tolerance. (Pubitemid 32976170)
12. Kuball J, Schmitz FW, Voss RH, et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005;22:117-129 • This study describes the generation of CD8-independent TCRs from HLA-transgenic mice. (Pubitemid 40143456)
13. Holler PD, Holman PO, Shusta EV, et al. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci USA 2000;97:5387-5392
14. Li Y, Moysey R, Molloy PE, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 2005;23:349-354 (Pubitemid 41094424)
15. Cohen CJ, Zhao Y, Zheng Z, et al. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006;66:8878-8886 (Pubitemid 44449206)
16. Scholten KB, Kramer D, Kueter EW, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006;119:135-145
17. Jorritsma A, Gomez-Eerland R, Dokter M, et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 2007;110:3564-3572 (Pubitemid 350159623)
18. Kuball J, Hauptrock B, Malina V, et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med 2009;206:463-475 • This study describes a new method to easily increase the avidity of TCR transduced T-cell by reducing TCR N-glycosylation.
19. Pittet MJ, Rubio-Godoy V, Bioley G, et al. α3 Domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol 2003;171:1844-1849 (Pubitemid 36966467)
20. Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999;20:180-183 (Pubitemid 29172281)
21. Berger C, Blau CA, Huang ML, et al. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 2004;103:1261-1269 • This study highlights the immunogeneicity of fusion proteins. (Pubitemid 38168636)
22. Daniels MA, Hogquist KA, Jameson SC. Sweet 'n' sour: the impact of differential glycosylation on T cell responses. Nat Immunol 2002;3:903-910
23. Lowe JB. Glycosylation, immunity, and autoimmunity. Cell 2001;104:809-812
24. Moody AM, Chui D, Reche PA, et al. Developmentally regulated glycosylation of the CD8αβ coreceptor stalk modulates ligand binding. Cell 2001;107:501-512 (Pubitemid 33152785)
25. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N- glycosylation. Nature 2001;409:733-739 (Pubitemid 32144520)
26. Holler PD, Chlewicki LK, Kranz DM. TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 2003;4:55-62 • This study shows that high-affinity TCRs engineered by display strategies can become self-reactive. (Pubitemid 36104709)
27. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95:2198-2203 (Pubitemid 30167714)
28. Theobald M, Biggs J, Hernandez J, et al. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-841 (Pubitemid 27119867)
29. Fernandez-Miguel G, Alarcon B, Iglesias A, et al. Multivalent structure of an αβT cell receptor. Proc Natl Acad Sci USA 1999;96:1547-1552 (Pubitemid 129656235)
30. Manolios N, Letourneur F, Bonifacino JS, Klausner RD. Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor. EMBO J 1991;10:1643-1651 (Pubitemid 21905630)
31. Rubinstein MP, Kadima AN, Salem ML, et al. Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol 2003;170:1209-1217 (Pubitemid 36139485)
32. Cooper LJ, Kalos M, Lewinsohn DA, et al. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000;74:8207-8212 (Pubitemid 30641669)
33. Voss RH, Kuball J, Engel R, et al. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol Res 2006;34:67-87 (Pubitemid 43780377)
34. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-223 (Pubitemid 26057556)
35. Sebestyen Z, Schooten E, Sals T, et al. Human TCR that incorporate CD3ζ induce highly preferred pairing between TCRα and β chains following gene transfer. J Immunol 2008;180:7736-7746
36. Teixeiro E, Daniels MA, Hamilton SE, et al. Different T cell receptor signals determine CD8+ memory versus effector development. Science 2009;323:502-505 • This study outlines the potential harm of altering the signaling domain in TCRs: a reduced T cell memory formation.
37. Garboczi DN, Ghosh P, Utz U, et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996;384:134-141 (Pubitemid 26386462)
38. Sun ZJ, Kim KS, Wagner G, Reinherz EL. Mechanisms contributing to T cell receptor signaling and assembly revealed by the solution structure of an ectodomain fragment of the CD3εγ heterodimer. Cell 2001;105:913-923 (Pubitemid 32635092)
39. Pecorari F, Tissot AC, Pluckthun A. Folding, heterodimeric association and specific peptide recognition of a murine αβ T-cell receptor expressed in Escherichia coli. J Mol Biol 1999;285:1831-1843 (Pubitemid 29060474)
40. Li ZG, Wu WP, Manolios N. Structural mutations in the constant region of the T-cell antigen receptor (TCR)β chain and their effect on TCR α and β chain interaction. Immunology 1996;88:524-530 (Pubitemid 26255120)
41. Boulter JM, Glick M, Todorov PT, et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng 2003;16:707-711 (Pubitemid 37314399)
42. Cohen CJ, Li YF, El-Gamil M, et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007;67:3898-3903 (Pubitemid 46762178)
43. Voss RH, Willemsen RA, Kuball J, et al. Molecular design of the Cαβ interface favors specific pairing of introduced TCRαβ in human T cells. J Immunol 2008;180:391-401
44. Heemskerk MH, Hagedoorn RS, van der Hoorn MA, et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007;109:235-243 • This study demonstrates that variable TCR chains have intrinsic qualities to promote pairing. (Pubitemid 46053064)
45. Richman SA, Aggen DH, Dossett ML, et al. Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain VαVβ fragments. Mol Immunol 2009;46:902-916
46. Blattman JN, Grayson JM, Wherry EJ, et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 2003;9:540-547 (Pubitemid 36597099)
47. Dudley M, Wunderlich J, Robbins P, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854 • This study demonstrates the efficacy of an adoptive immunotherapy with genetically unmodified T-cells in men. (Pubitemid 35231542)
48. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-305 • This study provides a rationale for transducing T-cells derived from central memory T-cells in order to achieve long term persistence of transferred T-cells.
49. Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009;113:1006-1015
50. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12:1160-1166 (Pubitemid 44527351)
51. Turk MJ, Guevara-Patino JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200:771-782 (Pubitemid 39299463)
52. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005;202:907-912 (Pubitemid 41396891)
53. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-129 (Pubitemid 44547756)
54. Backstrom BT, Milia E, Peter A, et al. A motif within the T cell receptor α chain constant region connecting peptide domain controls antigen responsiveness. Immunity 1996;5:437-447 (Pubitemid 26423472)
55. Teixeiro E, Daniels MA, Hausmann B, et al. T cell division and death are segregated by mutation of TCRβ chain constant domains. Immunity 2004;21:515-526 (Pubitemid 39370507)
56. Sahuquillo AG, Roumier A, Teixeiro E, et al. T cell receptor (TCR) engagement in apoptosis-defective, but interleukin 2 (IL-2)-producing, T cells results in impaired ZAP70/CD3-ζ association. J Exp Med 1998;187:1179-1192 (Pubitemid 28189108)
57. Teixeiro E, Fuentes P, Galocha B, et al. T cell receptor-mediated signal transduction controlled by the β chain transmembrane domain: apoptosis-deficient cells display unbalanced mitogen-activated protein kinases activities upon T cell receptor engagement. J Biol Chem 2002;277:3993-4002 (Pubitemid 34968654)
58. Pinthus JH, Waks T, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004;114:1774-1781 (Pubitemid 40385533)
59. Pinthus JH, Waks T, Kaufman-Francis K, et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 2003;63:2470-2476 (Pubitemid 36605185)
60. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994;91:4318-4322 (Pubitemid 24984900)
61. Altenschmidt U, Klundt E, Groner B. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol 1997;159:5509-5515 (Pubitemid 127470079)
62. Mamalaki A, Gritzapis AD, Kretsovali A, et al. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the γ-chain from Fc(ε) RI. Cancer Immunol Immunother 2003;52:513-522
63. Gritzapis AD, Mamalaki A, Kretsovali A, et al. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells. Br J Cancer 2003;88:1292-1300 (Pubitemid 36606349)
64. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13:5426-5435 (Pubitemid 47510370)
65. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9:279-286 (Pubitemid 36362782)
66. Loskog A, Giandomenico V, Rossig C, et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006;20:1819-1828 (Pubitemid 44574993)
67. Jensen MC, Cooper LJ, Wu AM, et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 2003;5:131-138 (Pubitemid 36596497)
68. Jensen M, Tan G, Forman S, et al. CD20 is a molecular target for scFvFc:ζ receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant 1998;4:75-83 (Pubitemid 128540943)
69. Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77:89-91 (Pubitemid 28425183)
70. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood 2000;96:785-793 (Pubitemid 30616838)
71. Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 1991;64:1037-1046 (Pubitemid 121001190)
72. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720-724 (Pubitemid 23028937)
73. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86:10024-10028 (Pubitemid 20030768)
74. Schaft N, Lankiewicz B, Drexhage J, et al. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNγ production. Int Immunol 2006;18:591-601
75. Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z. Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation. J Biol Chem 1997;272:8551-8557 (Pubitemid 27147820)
76. Mesturini R, Nicola S, Chiocchetti A, et al. ICOS cooperates with CD28, IL-2, and IFN-γ and modulates activation of human naive CD4+ T cells. Eur J Immunol 2006;36:2601-2612 (Pubitemid 44608444)
77. Rogers PR, Song J, Gramaglia I, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001;15:445-455 (Pubitemid 32907391)
78. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J Immunol 2004;172:104-113 (Pubitemid 38020461)
79. Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998;161:2791-2797 (Pubitemid 28425698)
80. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18:676-684 (Pubitemid 38500185)
81. Pule MA, Straathof KC, Dotti G, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005;12:933-941 (Pubitemid 41614489)
82. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001;248:67-76 (Pubitemid 32167025)
83. Friedmann-Morvinski D, Bendavid A, Waks T, et al. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 2005;105:3087-3093 (Pubitemid 40504325)
84. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-6115 (Pubitemid 44703776)
85. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24:e20-e22
86. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15:825-833 (Pubitemid 46432004)
87. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261-2271
88. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. PNAS 2002;99:16168-16173
89. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-1270 • This study demonstrates that transduction of virus-reactive T-cells with tumor-specific receptors can improve survival of transferred T-cells.
90. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004;199:885-894 (Pubitemid 38481080)
91. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-687 (Pubitemid 43237609)
92. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555 (Pubitemid 28406858)
93. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-2357 (Pubitemid 46218728)
94. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 1998;279:1737-1740 • This study outlines a recognition mechanism of tumors by γδ T-cells. (Pubitemid 28164472)
95. Gober HJ, Kistowska M, Angman L, et al. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-168 (Pubitemid 36152311)
96. Ferrarini M, Ferrero E, Dagna L, et al. Human γδ T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002;23:14-18
97. Lamb LS Jr, Lopez RD. γδ T cells: a new frontier for immunotherapy? Biol Blood Marrow Transplant 2005;11:161-168
98. Wilhelm M, Kunzmann V, Eckstein S, et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-206
99. Poccia F, Boullier S, Lecoeur H, et al. Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol 1996;157:449-461 (Pubitemid 26190580)
100. Loh EY, Wang M, Bartkowiak J, et al. Gene transfer studies of T cell receptor-gamma delta recognition. Specificity for staphylococcal enterotoxin A is conveyed by V gamma 9 alone. J Immunol 1994;152:3324-3332 (Pubitemid 24098028)
101. Bukowski JF, Morita CT, Tanaka Y, et al. V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J Immunol 1995;154:998-1006
102. van der Veken LT, Hagedoorn RS, van Loenen MM, et al. αβ T-cell receptor engineered γδ T cells mediate effective antileukemic reactivity. Cancer Res 2006;66:3331-3337
103. Anderson BE, Shlomchik WD, Shlomchik MJ. Recipient γδ T cells in graft-versus-host disease. Blood 2006;107:3808-3809
104. Halary F, Pitard V, Dlubek D, et al. Shared reactivity of Vδ2neg γδ T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 2005;201:1567-1578 (Pubitemid 40721002)
105. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-6115 (Pubitemid 44703776)